医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

CBI Pharma to Hold 6th Annual IVD Summit 2015 on March 12-13 in Shenzhen, China

2015年01月27日 PM02:16
このエントリーをはてなブックマークに追加


 

SHANGHAI

CBI Pharma, a subsidiary of ENMORE, will hold the 6th Annual IVD Summit 2015 (IVDS 2015) in Shenzhen, China on March 12-13, 2015. As the No.1 IVD industry summit in China, IVDS discusses industry policies and market trends and provides a good cooperation and communication platform for IVD industry players around the world.

China is the fastest increasing IVD market with a 16% average annual growth rate. At the same time, with the enhancement of China’s medical insurance policy and its popularization in rural areas, public awareness of medical treatment and healthcare will continue to rise. In the meantime, with the rapid growth of national economy and improvement of people’s living standards, the demand for IVD products will be sequentially increased. China’s IVD market holds tremendous potential.

However, China is faced with many restrictions like outdated laws and regulations, a low concentration rate for the industry, weak R&D capacity, lack of talent, intense homogenized competition and so on. To break the bottleneck, it’s necessary to enhance cooperation and communication among governments, manufacturers, institutions, end-users and investors.

IVDS 2015 will explore and present scientific, pragmatic, authoritative and up-to-date expertise and technologies to you. The participants will have great networking opportunities and get a thorough update about the policies and the market. Besides, cases will be studied to demonstrate how cutting-edge technologies have been turned into commercial success.

Topics to be covered include:

Development Tendency of IVD Industry during the “13th Five-year Plan” Period in China
Global IVD Industry and Segment Market Analysis
Market Opportunities of Wearable Medical Equipment
Application Tendency of Next-generation Sequencing
Present Situation and Outlook of Pediatric Infectious Disease Virus Reagents
Present Situation and Future Forecast on POCT Market in China
Pharmacogenomics and Individualized Therapy
Performance Evaluation of IVD Products

CONTACT

For more details on the conference, please contact:
CBI
Pharma
Jessica Quan, +86 (0)21 5155 0869
jessicaquan@enmore.com
Website:
http://ivdsummit.cbibiz.com/51321/index.html

同じカテゴリーの記事 

  • Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D
  • Takeda公布2023财年全年业绩和2024财年展望,确认对后期研发管线开发和提高核心营业利润率的承诺
  • Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
  • AMLにおける寛解期に残存するFLT3-ITD変異と移植後の転帰との間に重要な関連があることが研究によって判明
  • 研究表明AML缓解期残留FLT3-ITD突变与移植后结果之间存在重要联系